Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Royal Caribbean Cruises Ltd — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Royal Caribbean Cruises Ltd trades at $274.31 (market cap $75.29B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 14.5× Oruka Therapeutics Inc. Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| ORKA | RCL | |
|---|---|---|
Market Cap | $5.18B | $75.29B |
Volume | 490,798 | 1,401,290 |
Sector | Health | Consumer Cyclical |
52-Week High | $113.08 | $348.03 |
52-Week Low | $26.19 | $230.30 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $4.31B | $97.93B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royal Caribbean (RCL) trades at $274.33, down 2.26% today, with a bullish technical signal and strong fundamental recovery. The stock shows robust earnings momentum with Q1 and Q2 2026 beats, while Q3 expectations are high at $6.38 EPS. Revenue growth accelerated from $8.8B in 2022 to $17.9B in 2025, with net income margins improving to 23.54%. Recent news highlights the $3B Sandals resort acquisition as a strategic expansion beyond cruising.
RCL presents a compelling growth story with analyst consensus at Buy (53% of ratings) and a $344.17 price target offering 25% upside. Key risks include execution of the Sandals integration, fuel cost volatility ($1.34B projected for 2026), and high debt levels despite improving leverage. The stock's valuation at 17.4x P/E appears reasonable given 45% ROE and positive cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
